Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The company has a 50-day simple moving average of $48.90 and a 200-day simple moving average ... The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases ...

The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

By Keith Caulfield Following its first full week of activity, Bad Bunny’s Debí Tirar Más Fotos climbs 2-1 on the Billboard 200 albums chart (dated Jan. 25), scoring the superstar his fourth ...

However, biologics like Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) Dupixent (dupilumab) have paved the way for a new treatment paradigm, targeting specific inflammatory pathways to reduce ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...